Sanigen Q1 Sales Down 21%, Net Debt Ratio Soars; Capital Increase and CB Issuance

Q1 2026 revenue 3.31 billion won (down 21.4% YoY), operating loss 0.87 billion (vs 1.19 billion), net loss 0.90 billion (vs 1.62 billion)
Equity 1.59 billion won, net debt ratio 60.23% (from 30.26% at year-end 2025)
Illegal act receivables (fabricated transactions) 1.4 billion won fully provisioned
After reporting period: capital increase via third-party allotment (6,035,003+534,846 shares) and 5 billion won 2nd series CB issued
Correction report fixes XBRL errors and adds missing shareholder voting details
No dividends due to accumulated losses